title: Rise of plasma myeloperoxidase during interferon therapy.
abstract: The plasma myeloperoxidase (MPO) level was evaluated using a specific radio-immunoassay (RIA) for MPO in alpha 2b-interferon (IFN)-treated patients with chronic viral hepatitis. The plasma MPO was checked before and after the initial 2 weeks use of IFN at a dose of 6 x 10(6) U/day. The mean concentration of plasma MPO was found to be markedly higher after IFN therapy than that before the therapy (421.7 +/- 34.3 vs 242.9 +/- 23.0 ng/mL, P < 0.001). The plasma MPO negatively correlated with the granulocyte count (r = -0.37, P < 0.02) and the platelet count (r = 0.49, P < 0.01, while it positively correlated with serum alkaline phosphatase (ALP; r = 0.41, P < 0.03). The plasma MPO also showed a strong correlation with plasma polymorphonuclear granulocyte elastase (PMN elastase; r = 0.73, P < 0.001). Our study thus suggests that the increased release of MPO from destroyed granulocytes is responsible for the high concentrations of the plasma MPO in patients during IFN therapy, because the plasma MPO, PMN elastase and ALP abundant in granulocytes all increased in spite of a decrease in the granulocyte count. Granulocytopenia during IFN therapy may therefore be due to the increased destruction of granulocytes in addition to a direct suppression of the bone marrow by IFN.
authors.affiliation: Department of Internal Medicine, Fukuoka City Hospital, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Nakamuta
authors.forename: M
authors.initials: M
authors.lastname: Ohashi
authors.forename: T
authors.initials: T
authors.lastname: Fukutomi
authors.forename: Y
authors.initials: Y
authors.lastname: Tanabe
authors.forename: K
authors.initials: K
authors.lastname: Hiroshige
authors.forename: H
authors.initials: H
authors.lastname: Nawata
mesh_terms: D000380:Agranulocytosis / Q000209:etiology; D000469:Alkaline Phosphatase / Q000096:biosynthesis; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D006509:Hepatitis B / Q000201:enzymology / Q000628:therapy; D006526:Hepatitis C / Q000201:enzymology / Q000628:therapy; D006525:Hepatitis, Viral, Human / Q000201:enzymology / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count; D019272:Leukocyte Elastase; D010196:Pancreatic Elastase / Q000096:biosynthesis; D009195:Peroxidase / Q000096:biosynthesis / Q000097:blood*; D010976:Platelet Count; D011863:Radioimmunoassay; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D009195:Peroxidase; D000469:Alkaline Phosphatase; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase